BYTE51 is a Life Science data company which sells subscription access to $640B of VC Funding data to grow your business. Unlimited data downloads and API data access to your internal app and databases. Prospecting - Identify 20,000 private companies to increase your sales – Download companies by location, funding and clinical stage. Seed/Angel deals = $15B/4190 companies, Grant = $6B/2435 companies, Series A = $103B/ 3076 companies, Series B = $109B/1659 companies, Series C = $101B/835 companies. Research – In depth knowledge of the market landscape by 4,000 clinical indications and scientific approaches. $169 Billion invested in 790 Companies with Neurological Disorders. $53B invested in Orphan Diseases (272 companies), $29B in Parkinson's Disease (225 companies), $16B in Alzheimer's Disease (200 companies). Search which indications are getting the most funding? Who has raised the most capital in Neuro, Phase 2 clinical stage. Search - Who is the biggest investors and acquirers in Gene Therapy? Fund Raising – Search 14,000 VC Investors and syndicates globally. Identify prospective investor portfolios and secure your lead investor. Access how much capital competitors and comps have raised.

We raised $12.5M of capital, to launch CipherBio a data platform which aggregates $1.6 Trillion of Global VC Funding to empower Life Science Founders/CEOs to raise capital, VCs/PEs to source investments and Strategic Partners to acquire new clients. CipherBio provides Strategic Partners with $89 Billion of Series A/Seed VC funded data leads on new start-up companies for Sales teams (RMs) to acquire new deposit and debt loan clients to increase revenue.

We invested in 120 companies, over 5 funds ($1.1B AUM). Notable deals include Human Genome Sciences (Acquired by GSK for $3.6B), Illumina (ILMN $23B), Dicerna (Acquired by NVO $3.3B), Sirna (Acquired by MRK for $1.1B) and Exelixis (EXEL $10B). I was an investor in 12 Oxford portfolio companies and founding CEO of two start ups. For Oxford funds II, III, IV and V, I traveled with my partners to Dubai, Abu Dhabi, Oman, Kuwait, Tokyo and Russia to secure $950M of LP commitments. Thank you to the Oxford LPs, my Partners and to our Founders/CEOs for 18+ Brilliant Years at Oxford!

MedVest was a venture capital firm for J&J and Oak Investment Partners.